Lymphocytic Infiltration and Expression of Inducible Nitric Oxide Synthase in Human Duodenal and Colonic Mucosa Is a Characteristic Feature of Ankylosing Spondylitis

Journal of Rheumatology

Volumn 30, Issue 11, 2003, Pages 2428-2436

  Lamarque, Dominique ^a   Van Nhieu, Jeanne Tran ^b   Breban, Maxime ^b   Bernardeau, Christophe ^b   Martin Garcia, Nadine ^b   Szepes, Zoltan ^b   Delchier, Jean Charles ^b   Whittle, Brendan ^b   Claudepierre, Pascal ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b NONE

Author keywords

Ankylosing spondylitis; Colitis; Duodenum; Inflammation; Nitric oxide

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COLON MUCOSA; COLONOSCOPY; CONTROLLED STUDY; DUODENUM BIOPSY; DUODENUM MUCOSA; ENZYME ACTIVITY; GASTROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LAMINA PROPRIA; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOCHEMISTRY; SCORING SYSTEM; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CELL MOVEMENT; COLON; DUODENUM; GASTROSCOPY; HELICOBACTER PYLORI; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTESTINAL MUCOSA; LYMPHOCYTES; MIDDLE AGED; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; SPONDYLITIS, ANKYLOSING;

EID: 0042457141     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology 1989;96:339-44.
2. Cuvelier C, Barbatis C, Mielants H, De Vos M, Roels H, Veys E. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987;28:394-401.
3. Salzman AL. Nitric oxide in the gut. New Horiz 1995;3:352-64.
4. Boughton-Smith NK, Evans SM, Laszlo F, Whittle BJ, Moncada S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Br J Pharmacol 1993;110:1189-95.
5. Tepperman BL, Brown JF, Korolkiewicz R, Whittle BJ. Nitric oxide synthase activity, viability and cyclic GMP levels in rat colonic epithelial cells: effect of endotoxin challenge. J Pharmacol Exp Ther 1994;271:1477-82.
6. Tepperman BL, Brown JF, Whittle BJ. Nitric oxide synthase induction and intestinal epithelial cell viability in rats. Am J Physiol 1993;265:G214-8.
7. Lamarque D, Moran AP, Szepes Z, Delchier JC, Whittle BJ. Cytotoxicity associated with induction of nitric oxide synthase in rat duodenal epithelial cells in vivo by lipopolysaccharide of Helicobacter pylori: inhibition by superoxide dismutase. Br J Pharmacol 2000;130:1531-8.
8. Kiss J, Lamarque D, Delchier JC, Whittle BJ. Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Eur J Pharmacol 1997;336:219-24.
9. Blanchard HS, Dernis-Labous E, Lamarque D, et al. Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human beta 2 microglobulin transgenic rats. Eur Cytokine Netw 2001;12:111-8.
10. Kolios G, Rooney N, Murphy CT, Robertson DA, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. Gut 1998;43:56-63.
11. Hibbs JB Jr, Westenfelder C, Taintor R, et al, Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992;89:867-77.
12. Huang CJ, Stevens BR, Nielsen RB, et al. Interleukin-10 inhibition of nitric oxide biosynthesis involves suppression of CAT-2 transcription. Nitric Oxide 2002;6:79-84.
13. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
14. Majano PL, Garcia-Monzon C, Lopez-Cabrera M, et al. Inducible nitric oxide synthase expression in chronic viral hepatitis. Evidence for a virus-induced gene upregulation. J Clin Invest 1998;101:1343-52.
15. Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999;116:1319-29.
16. Salter M, Knowles RG, Moncada S. Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett 1991;291:145-9.
17. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996;110:1696-703.
18. Mielants H, Veys EM, Cuvelier C, De Vos M, Botelberghe L. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol 1985;12:294-8.
19. Grillet B, de Clerck L, Dequeker J, Rutgeerts P, Geboes K. Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy. Br J Rheumatol 1987;26:338-40.
20. Mielants H, Veys EM, Goemaere S, Goethals K, Cuvelier C, De Vos M. Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. J Rheumatol 1991;18:1542-51.
21. Cuvelier C, Mielants H, Quatacker J, De Vos M, Veys EM, Roels H. Spondylarthropathy and gut inflammation: immunopathogenetic mechanisms. Int J Tissue React 1992;14:203-9.
22. Cuvelier CA, De Wever N, Mielants H, De Vos M, Veys EM, Roels H. Expression of T cell receptors alpha beta and gamma delta in the ileal mucosa of patients with Crohn's disease and with spondylarthropathy. Clin Exp Immunol 1992;90:275-9.
23. Taha AS, Dahill S, Nakshabendi I, Lee FD, Sturrock RD, Russell RI. Duodenal histology, ulceration, and Helicobacter pylori in the presence or absence of non-steroidal anti-inflammatory drugs. Gut 1993;34:1162-6.
24. Wyatt JI, Rathbone BJ, Sobala GM, et al. Gastric epithelium in the duodenum: its association with Helicobacter pylori and inflammation. J Clin Pathol 1990;43:981-6.
25. Bjarnason I, Zanelli G, Smith T, et al. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology 1987;93:480-9.
26. Mielants H, De Vos M, Goemaere S, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases. II. Role of disease. J Rheumatol 1991;18:394-400.
27. Wendling D, Bidet A, Guidet M. Intestinal permeability in ankylosing spondylitis. J Rheumatol 1990;17:114-5.
28. Altomonte L, Zoli A, Veneziani A, et al. Clinically silent inflammatory gut lesions in undifferentiated spondyloarthropathies. Clin Rheumatol 1994;13:565-70.
29. Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994;37:23-31.
30. Simenon G, Van Gossum A, Adler M, Rickaert F, Appelboom T. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990;17:1491-4.
31. Colon AL, Menchen L, Lizasoain I, et al. Inducible nitric oxide synthase activity is expressed not only in inflamed but also in normal colonic mucosa in patients with ulcerative colitis: a potential prognostic marker. Am J Gastroenterol 2000;95:1371-3.
32. Kimura H, Miura S, Shigematsu T, et al. Increased nitric oxide production and inducible nitric oxide synthase activity in colonic mucosa of patients with active ulcerative colitis and Crohn's disease. Dig Dis Sci 1997;42:1047-54.
33. Ikeda I, Kasajima T, Ishiyama S, et al. Distribution of inducible nitric oxide synthase in ulcerative colitis. Am J Gastroenterol 1997;92:1339-41.
34. Kimura H, Hokari R, Miura S, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998;42:180-7.
35. Godkin AJ, De Belder AJ, Villa L, et al. Expression of nitric oxide synthase in ulcerative colitis. Eur J Clin Invest 1996;26:867-72.
36. Yan L, Vandivier RW, Suffredini AF, Danner RL. Human polymorphonuclear leukocytes lack detectable nitric oxide synthase activity. J Immunol 1994;153:1825-34.
37. Weinberg JB, Misukonis MA, Shami PJ, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995;86:1184-95.
38. Singer II, Kawka DW, Scott S, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology 1996;111:871-85.
39. Leonard N, Bishop AE, Polak JM, Talbot IC. Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment. J Clin Pathol 1998;51:750-3.
40. Dijkstra G, Moshage H, van Dullemen HM, et al. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J Pathol 1998;186:416-21.
41. Roberts PJ, Riley GP, Morgan K, Miller R, Hunter JO, Middleton SJ. The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon. J Clin Pathol 2001;54:293-7.
42. McCafferty DM, Mudgett JS, Swain MG, Kubes P. Inducible nitric oxide synthase plays a critical role in resolving intestinal inflammation. Gastroenterology 1997;112:1022-7.
43. van der Veen RC. Nitric oxide and T helper cell immunity. Int Immunopharmacol 2001;1:1491-500.
44. Boughton-Smith NK, Evans SM, Hawkey CJ, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993;342:338-40.
45. Cifone MG, D'Alo S, Parroni R, et al. Interleukin-2-activated rat natural killer cells express inducible nitric oxide synthase that contributes to cytotoxic function and interferon-gamma production. Blood 1999;93:3876-84.